🇺🇸 FDA

P0 · Therapeutic area intelligence

Infectious disease patent intelligence

Antiviral, antibacterial, and vaccine-related pharmaceutical patents.

Patents
1,469

Quick answer

1,469 US pharmaceutical patents in our index match Infectious disease title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 12226429

    Highly active compounds against COVID-19

    Atea Pharmaceuticals, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12226474

    Methods and compositions for treating infections

    Decoy Therapeutics Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12213973

    Bacterial nitric oxide synthase inhibitors

    Northwestern University · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12209256

    System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12209240

    Antisense antibacterial compounds and methods

    The Board of Regents of the University of Texas System · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12201683

    Methods for preventing dengue and hepatitis a

    Takeda Vaccines, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12201658

    Viral gene therapy as treatment for cholesterol storage disease or disorder

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12194090

    Tetanus vaccine platform for embedding COVID-19 vaccine

    Prime Bio, Inc. · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12194049

    Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection

    GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12186342

    Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, IL-15 and IL-15 receptor alpha

    The Regents of the University of California · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12188039

    Recombinant adeno-associated viral vector for gene delivery

    The Board of Regents of the University of Texas System · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12171822

    Infectious plasmodium sporozoites grown in vitro

    Sanaria Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12173307

    Methods for the purification of viral vectors

    BIOVERATIV THERAPEUTICS INC. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12173029

    Antiviral prodrugs, pharmaceutical formulations, and methods

    The Regents of the University of California · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12173289

    Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12172969

    Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof

    EVOFEM BIOSCIENCES, INC. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12168013

    Antiviral prodrugs and nanoformulations thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12161655

    Methods of treating mycobacterial infections using tetracycline compounds

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12162857

    Antiviral compounds

    Enanta Pharmaceuticals, Inc. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12145941

    Heterocyclic antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12145968

    Recombinant HIV-1 envelope proteins and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12138243

    Antiviral use of FABP4 modulating compounds

    CRESCENTA BIOSCIENCES · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12129476

    Methods for measuring the potency of AADC viral vectors

    VOYAGER THERAPEUTICS, INC. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12121580

    Antibacterial photodynamic therapy using copper-cysteamine nanoparticles

    The Board of Regents of the University of Texas System · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12121503

    Antiviral treatments

    BioCryst Pharmaceuticals, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12109258

    Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections

    Inovio Pharmaceuticals, Inc. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12104181

    Compositions and methods for treating viral infections targeting TRIM7

    The Board of Regents of the University of Texas System · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12091675

    Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12083162

    Universal nanosponge for treating respiratory viral infection

    The Regents of the University of California · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12084489

    Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12083151

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12077772

    Transgene cassettes, AAV vectors and AAV viral vectors for the expression of human codon-optimized SLC6A1

    The Board of Regents of the University of Texas System · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12077782

    Viral clearance by low pH hold

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12070495

    HIV RNA vaccines

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12064512

    Silyl lipids suitable for enhanced delivery of anti-viral therapeutics

    The Regents of the University of California · Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12065428

    Anti-viral compounds

    Aligos Therapeutics, Inc. · Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12059418

    Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12060566

    Self-inactivating lentiviral vector comprising a FOXP3 expression cassette

    The Regents of the University of California · Granted Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12053519

    HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12053520

    Glycan-masked engineered outer domains of HIV-1 gp120 and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12054493

    Hepatitis B antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12043660

    10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12037363

    Peptides for Covid-19 prevention and treatment

    SOTIRA COVID, LLC · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12036255

    Bacteriophage compositions and methods for treatment of bacterial infections

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12018082

    Methods and agents for treating infections

    The Regents of the University of California · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12011425

    Hepatitis B antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12006340

    Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

    Atea Pharmaceuticals, Inc. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11999777

    Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Infectious disease patents are indexed?

1,469 patents match our Infectious disease classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.